Abstract: According to some aspects, a quantum circuit is provided including a plurality of non-linear circuit elements coupled together in series and in parallel, such that at least two of the circuit elements are coupled together in series and at least two of the circuit elements are coupled together in parallel, wherein the quantum circuit is configured to act as an amplifier.

Abstract: According to some aspects, a quantum information system is provided that includes an ancilla qubit; a qudit coupled to the ancilla qubit, a detector configured to generate a detection result based on a quantum state of the ancilla qubit, and a driving source coupled to the qudit and the ancilla qubit and configured to apply at least one qudit driving signal to the qudit based on the detection result and at least one qubit driving signal to the qudit based on the detection result.

Abstract: Systems and methods for rapidly analyzing cell containing samples, for example to identify morphology or to localize and quantitate biomarkers are disclosed.

Abstract: Methods and structures for forming epitaxial layers of Ill-nitride materials on patterned foreign substrates with low stacking fault densities are described. Semipolar and nonpolar orientations of GaN that are essentially free from stacking faults may be grown from crystal-growth facets of a patterned substrate. Etching can be used to remove stacking faults if present. Crystal growth with an impurity can eliminate crystal growth from a facet that is responsible for stacking fault formation and permit substantially stacking-fault-free growth of the Ill-nitride material.

Abstract: Techniques for managing forwarding configurations in a data communications network include accessing, at least one controller, a packet-processing policy defined by a user in a general-purpose programming language other than a programming language of data forwarding element forwarding rules, the packet-processing policy specifying how data packets are to be processed through the data communications network via the at least one controller. A forwarding configuration for at least one data forwarding element in the data communications network may be derived from the user-defined packet-processing policy, and may be applied to the at least one data forwarding element.

Abstract: The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

Abstract: Seven protective alleles for IgA nephropathy have been discovered that can be identified by analyzing a DNA sample for seven respective SNPs. A method is provided for identifying and treating subjects at risk of developing IgA neuropathy based on a new seven-SNP genetic risk score. Also provided are screening methods to identify compounds that bind to and reduce the expression or biological activity of a either CFHR1 or CFHR3.

Abstract: Efficient encoding of signals in an MRI image is achieved through a combination of parallel receiver coils, and nonlinear gradient encoding that varies dynamically in such a manner as to impose a unique phase/frequency time varying signal on each pixel in the field of view. Any redundancies are designed such that they are easily resolved by the receiver coil sensitivity profiles. Since each voxel has an essentially identifiable complex temporal signal, spatial localization is easily achieved with only a single echo acquisition.

Abstract: The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purify and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders.

Abstract: The present disclosure describes biaryl triazole compounds, as well as their compositions and methods of use. The compounds inhibit the activity of macrophage migration inhibitory factor and are useful for the treatment of diseases, e.g., inflammatory diseases and cancer.

Abstract: The present invention provides a method of treating melanoma and other cancers in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an herbal extract of PHY906 or Scutellaria baicalensis, a fraction thereof, or any active chemical present in the herbal extract or fraction thereof, and one or more immune checkpoint inhibitors. In certain embodiments, the method further comprises administering at least one herbal extract, a fraction thereof, or any active chemical present in the herbal extract or fraction thereof, of at least one herb selected from the group consisting of Glycyrrhiza uralensis, Paeonia lactiflora, and Ziziphus jujuba. The methods of the invention are useful for treating cancer such as melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer, and/or pancreatic cancer.

Abstract: A low-noise directional amplifier includes a first port, a second port, a first coupler and a second coupler. The first port is coupled to a first coupler. The low-noise directional amplifier also includes at least two phase preserving amplifiers, a first phase preserving amplifier connected to the first coupler and a second coupler, and the second phase preserving amplifier connected to the first coupler and the second coupler.

Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia.

Abstract: A method for decreasing formation of one or more chemiexcitation-induced dark cyclobutane pyrimidine dimers (dCPDs) in a cell or DNA molecule in a subject, who has been exposed to UV radiation, is provided. The method comprises administering to the subject an effective amount of a dCPD quencher within 8 hours after the exposure. The dCPD quencher is selected from the group consisting of ellagic acid, Porphyra Umbilicalis Extract (including Porphyra Umbilicalis Extract (and) Sodium Lactate (and) Lecithin), mycosporine-like amino acids (MAAs) and synthetic analogues thereof, Scutellaria Baicalensis Root Extract, Chrysanthemum Morifolium Leaf Extract, ferulic acid, fused-ring cyanoacrylates, curcumin, epigallocatechin gallate, Scutellaria Baicalensis Root Extract (and) Acacia Catechu Wood Extract, sorbic acid, Polygonum Cuspidatum Root Extract, Acacia Catechu Extract, dipicolinic acid, squalene, Lonicera Japonica (Honeysuckle) Flower Extract, beta-carotene and combinations thereof.

Abstract: The present invention includes compositions and methods of inhibiting or activating TLR7 signaling. In one aspect, a composition includes an inhibitor of TLR7 signaling is described, where the inhibitor of TLR7 signaling is a TLR7 inhibitory oligonucleotide, a TLR7 antibody, or a TLR7 antagonist. In another aspect, a composition and method are described for preventing and treating viral infection of a T cell in a subject. Methods for decreasing T cell proliferation by administering a composition with a TLR7 ligand or agonist or inducing T cell anergy in a subject by stimulating T cells with a TLR7 ligand or agonist are also described.

Abstract: A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Examplary macrophage inhibitors include bisphosphonates, anti-folate drugs and antibodies, preferably in a controlled release or liposomal formulation.

Abstract: A method for analyzing spatial point patterns and visualizing the results is presented. The method includes simulating at least one point set within a region using a point process, dividing the region into a plurality of elements, determining scores for both real data and simulated data for each element by weighting the point sets within a domain of a predetermined kernel. The method further includes comparing scores for each element, computing confidence intervals for at least one confidence level having a predetermined statistical significance; and providing a visualization to identify clusters and exclusion zones.

Abstract: Provided herein are ALK regulators for the treatment of diseases and disorders. For example, presented herein are ALK regulators, e.g., ALK activators, and methods of treatment and/or prevention of diseases, including neurodegenerative, neuromuscular and cognitive diseases or disorders, and methods of enhancing cognitive abilities using ALK regulators, e.g., ALK activators. Also provided herein are ALK regulators, e.g., ALK inhibitors, and methods of treatment and/or prevention of diseases such as hyperproliferative and neoplastic disorders associated with cells that express ALK, e.g., cells that exhibit increased or constitutive levels of ALK tyrosine phosphorylation using such ALK regulators, e.g., ALK inhibitors. Pharmaceutical compositions of said ALK regulators, e.g, ALK activators and inhibitors are likewise provided.

Abstract: Site-selective functionalized glycopeptide antibiotics, methods of making and using are described herein. The compounds exhibit improved activity against methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-sensitive S. aureus (VSE), vancomycin-resistant enterococci (VRE), or combinations thereof. The compounds can be administered as the neutral free acid or free base or can be administered as a pharmaceutically acceptable acid-addition or base-addition salt. The compounds can be formulated with one or more pharmaceutically acceptable excipients to prepare pharmaceutical compositions. The compounds can be administered by a variety of routes of administration including enteral, parenteral, topical, or transmucosal.

Abstract: Advantageous instruments, assemblies and methods are provided for undertaking surgical procedures (e.g., cardiovascular interventional procedures). The present disclosure provides advantageous devices, assemblies and methods in the field of cardiac surgery and interventional cardiology procedures. Advantageous protection assemblies/devices (e.g., aortic arch embolic protection assemblies/devices) and related methods of use are provided. The present disclosure relates generally to embolic protection devices for use in the aortic arch to protect the distal vasculature during cardiac surgery and interventional cardiology procedures. An exemplary embolic protection device can take the form of an expandable/inflatable bladder member in a curved tube shape. The present disclosure provides advantageous (embolic) protection devices/assemblies, systems incorporating such devices/assemblies, and methods of use of such devices/assemblies for the benefit of such surgical practitioners and their patients.